EPISODE · May 14, 2026 · 23 MIN
Kurma’s €215m Fund And What It Says About European Funding Environment
from Citeline Podcasts · host Norstella
Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment
What this episode covers
Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment
NOW PLAYING
Kurma’s €215m Fund And What It Says About European Funding Environment
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m